Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Trends in Outcomes, and Length and Costs of Hospitalization in Patients with Intracerebral Hemorrhage in United States
Cerebrovascular Disease and Interventional Neurology
Cerebrovascular Disease and Interventional Neurology Posters (7:00 AM-5:00 PM)
077
To determine trends pertaining in-hospital outcomes in patients with
intracerebral hemorrhage using nationally representative data.
It remains unclear whether there is any improvement in outcomes of patients
with intracerebral hemorrhage over the last decade.
We determined the national estimates of intracerebral hemorrhage admissions
from 2005 to 2014 and associated in-hospital outcomes, length of stay, mortality, and cost
incurred using the Nationwide Inpatient Survey (NIS) data. The NIS is the largest all-
payer inpatient care database in the US and contains data from 986 hospitals
approximating a 20% stratified sample of US hospitals. Outcome was classified as none to
minimal disability, moderate to severe disability, and death based on discharge destination.
In the 10-year period, there were 70,637 admissions for intracerebral
hemorrhage (annual estimate 80804 in 2005 to 109930 in 2014). There was a significant
reduction in in-hospital mortality in patients with intracerebral hemorrhage from 30% to
23% (trend test, p < 0.0001). There was a trend towards increase in proportion of patients
with moderate to severe disability (trend test, p < 0.097). The mean length of
hospitalization increased from 8.58 to 9.23 (trend test, p < 0.0001) and cost of
hospitalization increased from 50532.1 to 110932.1 (trend test, p < 0.0001).
The mortality in patients with intracerebral hemorrhage has decreased but
there is increased rates of moderate to severe disability, length of hospitalization, and
hospitalization cost over the last decade.
Authors/Disclosures
Mohammad Rauf A. Chaudhry, MD
PRESENTER 		Dr. Chaudhry has nothing to disclose.
Hussan Gill Mr. Gill has nothing to disclose.
Baljinder Singh, MD Dr. Singh has nothing to disclose.
Mohammad Ghatali, MD (Texas Tech Health Science Center) Dr. Ghatali has nothing to disclose.
Harathi Bandaru, MD Dr. Bandaru has nothing to disclose.
Anantha Vellipuram, MD Dr. Vellipuram has nothing to disclose.
Alberto Maud, MD (Paul L. Foster School of Medicine Texas Tech UHSC El Paso, Texas) Dr. Maud has nothing to disclose.
Rakesh Khatri, MD, FÂ鶹´«Ã½Ó³»­ Dr. Khatri has received personal compensation in the range of $0-$499 for serving as a Survey consultant with Alpha insight . Dr. Khatri has received personal compensation in the range of $0-$499 for serving as a Survey consultant with Survey company .
Gustavo J. Rodriguez, MD (Gustavo J. Rodriguez) Dr. Rodriguez has nothing to disclose.
Salvador Cruz-Flores, MD, FÂ鶹´«Ã½Ó³»­ (Paul L. Foster School of Medicine Texas Tech University Health Sciences Center) The institution of Dr. Cruz-Flores has received research support from University of Texas System.
Hamza I. Maqsood, MD (Dept of Neurology) Dr. Qureshi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AstraZeneca.